Vaccine

Details Vaccine Vaccine

1999-06-23

2002-07-09

Housel, James (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Virus or component thereof

C424S093100, C424S093200, C424S093600, C435S235100, C435S236000, C435S325000, C435S237000

Reexamination Certificate

active

06416764

ABSTRACT:

Bovine virus diarrhoea virus (BVDV) is extremely common in cattle in the UK, the remainder of Western Europe, North America, Australia and Africa. Infection with this virus may result in a variety of syndromes and pathologies influenced largely by the age of animals when first infected. In young, previously uninfected calves the virus causes a transient infection. This is associated with leucopenia, and an interrelated period of immunosuppressive and increased susceptibility to infection with other microorganisms. BVDV is, after RSV (respiratory syncitial virus), probably the most important virus associated with outbreaks of respiratory disease in young housed calves and because of its immuno-suppressive effect it may be involved in other calf infections, for example enteritis. This virus is also considered to be a major contributor to disease in “feedlot calves” in the USA and Canada. Following recovery, animals exhibit a degree of immunity to reinfection. However, this immunity appears not to be absolute or lifelong.
More serious problems result from infection of pregnant cattle. Abortion may ensure or alternatively deformities may be produced in the foetus that is carried to term; these deformities may result from exposure to virus at the time when immunocompetence is developing and could be the result of an incomplete immune response. Infection of the feotus before immunocompetence develops can result in the foetus remaining viraemic through the period of gestation and the subsequent birth of a calf that remains persistently viraemic, with a non-cytopathogenic form of the virus, and specifically immunotolerant to BVDV for life. Such calves are the animals that die later of mucosal disease; an event triggered by superinfection with a cytopathogenic variant of BVDV.
It has been estimated that about 0.4% of apparently normal beef calves in the UK are viraemic and these animals represent a major source of infection on farms.
Traditionally, viral vaccines fall into two classes: live vaccines containing live viruses which have been treated or grown (attenuated) in such a way as to make them less pathogenic, and vaccines containing killed (inactivated) virus particles. In the context of BVDV, the viruses themselves may be cytopathogenic or non-cytopathogenic. Thus, in principle, four main classes of BVDV vaccine could exist, although the vast majority of commercial vaccines are based on the cytopathogenic virus. Moreover, it is thought by many that live vaccines are unacceptable because live cytopathogenic vaccine strains may produce death from mucosal disease in persistently viraemic animals, and live non-cytopathogenic virus vaccine may infect the foetus in pregnant cattle and result in any of the diseases outlined above.
Infection via the respiratory tract is probably the most important route of transmission of the virus on farms and protection against spread via this route would be expected to have a major beneficial effect in controlling disease due to BVDV.
Parenteral vaccination with inactivated BVDV protected against respiratory infection. In one experiment all of 5 vaccinated calves were resistant to respiratory challenge and all of 5 controls become infected.
The killed BVDV antigens tested induced the production of high titres of neutralising antibodies. These were shown to rise from less than 50 before vaccination to greater than or equal to 2,000-10,000 units after vaccination.


REFERENCES:
patent: 3122477 (1964-02-01), Beckenhauer et al.
patent: 3293129 (1966-12-01), Baker
patent: 3346456 (1967-10-01), Baker
patent: 3577525 (1971-05-01), Baker
patent: 3838004 (1974-09-01), Mebus et al.
patent: 3839556 (1974-10-01), Mebus et al.
patent: 3869547 (1975-03-01), Mebus et al.
patent: 3873422 (1975-03-01), Mebus
patent: 3914408 (1975-10-01), Mebus
patent: 3919044 (1975-11-01), Melnick et al.
patent: 3919412 (1975-11-01), Mebus
patent: 3919413 (1975-11-01), Mebus
patent: 3925544 (1975-12-01), Sheckmeister et al.
patent: 4618493 (1986-10-01), Delgoffe et al.
patent: 4714678 (1987-12-01), Delgoffe et al.
patent: 4806350 (1989-02-01), Gerber
patent: 4900549 (1990-02-01), De Vries et al.
patent: 0 106 831 (1984-04-01), None
patent: 0 109 942 (1984-05-01), None
patent: 0 208 507 (1987-01-01), None
patent: 0 231 039 (1987-08-01), None
patent: 0 436 620 (1991-07-01), None
patent: 992330 (1965-05-01), None
patent: 1023526 (1966-03-01), None
patent: 1 401 565 (1975-07-01), None
patent: 1402565 (1975-07-01), None
patent: 1560344 (1980-02-01), None
patent: 2079786 (1982-01-01), None
patent: 48-2766 (1973-01-01), None
patent: 55-31058 (1980-03-01), None
US 6,156,559, 12/2000, Howard (withdrawn)
McClurkin et al. 1978. Selected isolates of bovine viral diarrhea (BVD) virus propagated on bovine turbinate cells: virus titer and soluble antigen production as factors in immnogenicity of killed BVD virus. Archives of Virology. vol. 58, pp. 119-125.*
Pocock et al. 1987. Variation in the intracellular polypeptide profiles from different isolates of bovine virus diarrhea virus. Archives of Virology. Vo. 94 (1-2), pp. 45-53. Abstract only.*
Morein. 1987. Potentiation of the immune response by immunization with antigens in defined multimeric physical forms. Veterinary Immunology and Immunopathology. vol. 17, pp. 153-159.*
Howard et al. 1987 Comparison by the neutralisation assay of pairs of non-cytopathogenic and cytopathogenic strains of bovine virus diarrhoea virus isolated fromn cases of mucosal disease. Veterinary Microbiology. vol. 13 (4), pp. 361-369. Abstract only.*
Comment “BVDV: breaking the cycle of infection,”The Veterinary Record, Jul. 15, 1995, p. 53.
Vaccination-challenge Experiments Table, 1 sheet.
“Vaccination Helps Cut Fertility Costs,”Dairy Farmer, Jul. 1, 1998, 1 sheet.
“Bovidec® Controlling BVD Infertility,” C-Vet, 3 sheets.
“Triangle 1—Bovine Virus Diarrhea Vaccine,” Fort Dodge, 2 sheets.
“Bovine Viral Diarrhoea,”OIE Manual, 1996, Chapter X.5. Not In the Code, pp. 651-659.
Barei, S. et al., “Comparison of the Potency of Cattle of Trivalent FMD Caccines Adjuvanted by Aluminum Hydroxide-Saponin or Oil Emulsion,”Zbl. Vet. Med. B.,26 (1979) pp. 464-460.
Bates, Andrew, “Light at the End of the Tunnel,”BCVA Congress Times, Apr. 22, 1998, pp. 1-2.
Bittle, J.L. et al., “Carriers and Adjuvants for Chemically Synthesized Antigens,”Advances in Carriers and Adjuvants for Veterinary Biologics, (1986) 1stEdition, pp. 151-156.
Brownlie, J. et al., “Experimental Infection of Cattle in Early Pregnancy with a Cytopathic Strain of Bovine Virus Diarrhoea Virus,”Research in Veterinary Science, 1989, 46, pp. 307-311.
Brownlie, J. et al., “Experimental Production of Fatal Mucosal Disease in Cattle,”The Veterinary RecordJun. 2, 1984, pp. 535-536.
Brownlie, J. et al. “Pathogenesis and Epidemiology of Bovine Virus Diarrhoea Virus Infection of Cattle,”Ann Rech Vet, 1987, 18, pp. 157-166.
Brownlie, J. et al., Protection of the Bovine Fetus from Bovine Viral Diarrhoea Virus by Means of a New Inactivated Vaccine,The Veterinary Record, Jul. 15, 1995, pp. 58-63.
Brownlie, J. et al., “Scientific Reports: Cattle—Mucosal Disease,” Annual Report of the Institute for Animal Health, 1987, p. 20.
Brownlie, Joe, “Clinical Aspects of the Bovine Virus Diarrhoea/Mucosal Disease Complex in Cattle,”In Practice, Nov. 1985, pp. 195-202.
Browlie, Joe, “The Pathways for Bovine Virus Diarrhoea Virus Biotypes in the Pathogenesis of Disease,”Arch Virol, 1991, Suppl. 3, pp. 79-96.
Corapi, Wayne V. et al., “Monoclonal Antibody Analysis of Cytopathic and Noncytopathic Viruses from Fatal Bovine Viral Diarrhea Virus Infections,” Journal of Virology, Aug. 1988, pp. 2823-2827.
Dalsgaard K., et al., Vaccination of Pigs Against Hog Cholera (Classic Swine Ferer) with a Detergent Split Vaccine,Acta. vet. scan.,(1976) 17, 465-474.
Dalsgaar, Kristian et al., “Classical and New Approaches to Adjuvant Use in Domestic Food Animals,”Advances in Veterinary Science and Comparative Medicine, (1990) vol. 35, pp. 121-160.
Dalsgaard, Kristian, “Saponin Adjuvants,”Archive für die gesamte Virusforschung, (1974) 44, pp. 243-254.
Dalsgaard, Kristian, “

Affiliated with

Also associated with

Rating

Vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vaccine will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2910313